Statistics

Total Visits

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)27

Select a period of time:

Number of views in the range

Views
Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)2

Views

Views
June 20250
July 20251
August 20250
September 20251
October 20250
November 20250
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States1
Venezuela1
 

Top cities views

Views
Dallas1